Martuza Sarwar1, Sabina Sandberg1, Per-Anders Abrahamsson2, Jenny L Persson3. 1. Division of Experimental Cancer Research, Department of Laboratory Medicine, Malmö, CRC, Lund University, Malmö, Sweden. 2. Department of Clinical Sciences, Division of Urologic Research, Skåne University Hospital, Lund University, Malmö, Sweden. 3. Division of Experimental Cancer Research, Department of Laboratory Medicine, Malmö, CRC, Lund University, Malmö, Sweden. Electronic address: jenny_l.persson@med.lu.se.
Abstract
OBJECTIVES: In the present study, we investigated whether the cyclic adenosine monophosphate (cAMP)-activated protein kinase A (PKA) pathway may regulate the expression of AR and prostate-specific antigen (PSA) and whether there is a correlation between the expression of cAMP/PKA-associated genes and androgen receptor (AR) in patients with prostate cancer (CaP). MATERIALS AND METHODS: The functional studies were performed in LNCaP and PC3 cell lines. Data on the mRNA expression of sets of genes in human clinical samples, including prostate tissues from organ donors, prostate primary cancer, and metastatic cancer, were extracted from the National Center for Biotechnology Informations Gene Expression Omnibus (GEO) database. Statistical tests were applied. RESULTS: We showed that elevated levels of cAMP/PKA pathways induced an increased expression of AR and PSA proteins in LNCaP cells in the absence of androgen. A cAMP-associated phosphodiesterase-4 (PDE4) inhibitor, rolipram induced an up-regulation in AR expression, whereas a cAMP enhancer, forskolin increased PSA level without affecting AR expression. Forskolin treatment increased the level of PKA R1α in LNCaP cells, but remarkably inhibited R1α expression in aggressive PC3 cells. In patients with CaP, we found that the expression of genes encoding R1α and phosphodiesterase-4B was statistically significantly lower in the metastatic specimens than that in the primary CaP specimens or in the normal prostate tissues (P<0.01) and was reversely correlated with AR expression. Conversely, AR and PRKAR2B mRNA expressions were significantly higher in metastatic lesions than those in the primary CaP specimens or in the normal prostate tissues (P<0.01). CONCLUSION: Our study revealed a novel mechanism to precisely define the functional and clinical interrelationship between the cAMP/PKA pathway and AR signaling in the development of androgen-independent growth of CaPs and metastasis progression.
OBJECTIVES: In the present study, we investigated whether the cyclic adenosine monophosphate (cAMP)-activated protein kinase A (PKA) pathway may regulate the expression of AR and prostate-specific antigen (PSA) and whether there is a correlation between the expression of cAMP/PKA-associated genes and androgen receptor (AR) in patients with prostate cancer (CaP). MATERIALS AND METHODS: The functional studies were performed in LNCaP and PC3 cell lines. Data on the mRNA expression of sets of genes in humanclinical samples, including prostate tissues from organ donors, prostate primary cancer, and metastatic cancer, were extracted from the National Center for Biotechnology Informations Gene Expression Omnibus (GEO) database. Statistical tests were applied. RESULTS: We showed that elevated levels of cAMP/PKA pathways induced an increased expression of AR and PSA proteins in LNCaP cells in the absence of androgen. A cAMP-associated phosphodiesterase-4 (PDE4) inhibitor, rolipram induced an up-regulation in AR expression, whereas a cAMP enhancer, forskolin increased PSA level without affecting AR expression. Forskolin treatment increased the level of PKA R1α in LNCaP cells, but remarkably inhibited R1α expression in aggressive PC3 cells. In patients with CaP, we found that the expression of genes encoding R1α and phosphodiesterase-4B was statistically significantly lower in the metastatic specimens than that in the primary CaP specimens or in the normal prostate tissues (P<0.01) and was reversely correlated with AR expression. Conversely, AR and PRKAR2B mRNA expressions were significantly higher in metastatic lesions than those in the primary CaP specimens or in the normal prostate tissues (P<0.01). CONCLUSION: Our study revealed a novel mechanism to precisely define the functional and clinical interrelationship between the cAMP/PKA pathway and AR signaling in the development of androgen-independent growth of CaPs and metastasis progression.
Authors: Rodrigo B de Alexandre; Anelia D Horvath; Eva Szarek; Allison D Manning; Leticia F Leal; Fabio Kardauke; Jonathan A Epstein; Dirce M Carraro; Fernando A Soares; Tatiyana V Apanasovich; Constantine A Stratakis; Fabio R Faucz Journal: Endocr Relat Cancer Date: 2015-05-15 Impact factor: 5.678
Authors: Ginny L Powers; Kimberly D P Hammer; Maribella Domenech; Katsiaryna Frantskevich; Rita L Malinowski; Wade Bushman; David J Beebe; Paul C Marker Journal: Mol Cancer Res Date: 2014-08-22 Impact factor: 5.852
Authors: Sazzad Hassan; Ashok Pullikuth; Kyle C Nelson; Anabel Flores; Yelena Karpova; Daniele Baiz; Sinan Zhu; Guangchao Sui; Yue Huang; Young A Choi; Ralph D'Agostino; Ashok Hemal; Urs von Holzen; Waldemar Debinski; George Kulik Journal: Mol Cancer Res Date: 2020-09-14 Impact factor: 5.852
Authors: Yao Wang; Rohit Ramakant Jadhav; Joseph Liu; Desiree Wilson; Yidong Chen; Ian M Thompson; Dean A Troyer; Javier Hernandez; Huidong Shi; Robin J Leach; Tim H-M Huang; Victor X Jin Journal: Sci Rep Date: 2016-02-29 Impact factor: 4.379
Authors: Shu Xia; Manish Kohli; Meijun Du; Rachel L Dittmar; Adam Lee; Debashis Nandy; Tiezheng Yuan; Yongchen Guo; Yuan Wang; Michael R Tschannen; Elizabeth Worthey; Howard Jacob; William See; Deepak Kilari; Xuexia Wang; Raymond L Hovey; Chiang-Ching Huang; Liang Wang Journal: Oncotarget Date: 2015-06-30
Authors: René Böttcher; Kalyan Dulla; Dianne van Strijp; Natasja Dits; Esther I Verhoef; George S Baillie; Geert J L H van Leenders; Miles D Houslay; Guido Jenster; Ralf Hoffmann Journal: Oncotarget Date: 2016-10-25